Literature DB >> 9915899

Aurothioglucose inhibits murine thioredoxin reductase activity in vivo.

A D Smith1, C A Guidry, V C Morris, O A Levander.   

Abstract

Gold (I)-containing compounds, including aurothioglucose (ATG), are potent in vitro inhibitors of several selenocysteine-containing enzymes. Gold compounds have also been shown to potentiate the virulence of several viruses in mice, including coxsackievirus, implicated as a possible infectious agent in Keshan disease. One possible mechanism by which gold compounds may be increasing the virulence of viral infections in mice is by acting as a selenium antagonist in vivo and inducing oxidative stress. To investigate the possible role of gold compounds in inducing oxidative stress in mice, we assessed the ability of ATG administered in vivo to inhibit the activity of the selenocysteine-containing enzymes thioredoxin reductase (TR) and glutathione peroxidase (GPX1). Doses as low as 0. 025 mg ATG/g body weight caused significant and prolonged inhibition of TR activity in all tissues examined. No such inhibition of GPX1 activity was seen, indicating differential in vivo sensitivity of the enzymes to inhibition by ATG. In liver and heart, some recovery of TR activity was observed after a 7-d period, but no recovery was observed in pancreas or kidney. Because TR is involved in several important cellular redox functions, its inhibition most likely will affect multiple cellular processes. These results indicate that in vivo administration of ATG results in significant and long-lasting inhibition of TR activity. Such inhibition of TR could lead to increased levels of oxidative stress in vivo, thereby increasing the virulence of several viruses including the coxsackievirus.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9915899     DOI: 10.1093/jn/129.1.194

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  19 in total

1.  Investigations of the catalytic mechanism of thioredoxin glutathione reductase from Schistosoma mansoni.

Authors:  Hsin-Hung Huang; Latasha Day; Cynthia L Cass; David P Ballou; Charles H Williams; David L Williams
Journal:  Biochemistry       Date:  2011-06-10       Impact factor: 3.162

Review 2.  Thioredoxin reductase.

Authors:  D Mustacich; G Powis
Journal:  Biochem J       Date:  2000-02-15       Impact factor: 3.857

3.  Participation of nuclear factor (erythroid 2-related), factor 2 in ameliorating lithocholic acid-induced cholestatic liver injury in mice.

Authors:  K P Tan; G A Wood; M Yang; S Ito
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

4.  Inhibition of thioredoxin reductase 1 by porphyrins and other small molecules identified by a high-throughput screening assay.

Authors:  Stefanie Prast-Nielsen; Thomas S Dexheimer; Lena Schultz; William C Stafford; Qing Cheng; Jianqiang Xu; Ajit Jadhav; Elias S J Arnér; Anton Simeonov
Journal:  Free Radic Biol Med       Date:  2011-01-22       Impact factor: 7.376

Review 5.  The redox biology of schistosome parasites and applications for drug development.

Authors:  Hsin-Hung Huang; Coraline Rigouin; David L Williams
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

6.  Oxidant-mediated modification of the cellular thiols is sufficient for arginase activation in cultured cells.

Authors:  Efemwonkiekie W Iyamu; Harrison A Perdew; Gerald M Woods
Journal:  Mol Cell Biochem       Date:  2011-09-15       Impact factor: 3.396

7.  Thioredoxin Reductase Inhibition Attenuates Neonatal Hyperoxic Lung Injury and Enhances Nuclear Factor E2-Related Factor 2 Activation.

Authors:  Qian Li; Stephanie B Wall; Changchun Ren; Markus Velten; Cynthia L Hill; Morgan L Locy; Lynette K Rogers; Trent E Tipple
Journal:  Am J Respir Cell Mol Biol       Date:  2016-09       Impact factor: 6.914

8.  Induction of mitochondrial permeability transition by auranofin, a gold(I)-phosphine derivative.

Authors:  Maria Pia Rigobello; Guido Scutari; Rita Boscolo; Alberto Bindoli
Journal:  Br J Pharmacol       Date:  2002-08       Impact factor: 8.739

9.  Thioredoxin-related mechanisms in hyperoxic lung injury in mice.

Authors:  Trent E Tipple; Stephen E Welty; Lynette K Rogers; Thomas N Hansen; Young-Eun Choi; James P Kehrer; Charles V Smith
Journal:  Am J Respir Cell Mol Biol       Date:  2007-06-15       Impact factor: 6.914

10.  Augmented antitumor effects of combination therapy of cisplatin with ethaselen as a novel thioredoxin reductase inhibitor on human A549 cell in vivo.

Authors:  Qiang Tan; Jing Li; Han-wei Yin; Li-hui Wang; Wan-chen Tang; Fang Zhao; Xin-min Liu; Hui-hui Zeng
Journal:  Invest New Drugs       Date:  2009-03-07       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.